1984 related articles for article (PubMed ID: 25578255)
1. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
2. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
3. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
[TBL] [Abstract][Full Text] [Related]
4. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
5. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion.
Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S
Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942
[TBL] [Abstract][Full Text] [Related]
6. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
7. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration.
Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I
Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701
[TBL] [Abstract][Full Text] [Related]
8. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
[TBL] [Abstract][Full Text] [Related]
10. Spatial Correspondence Between Intraretinal Fluid, Subretinal Fluid, and Pigment Epithelial Detachment in Neovascular Age-Related Macular Degeneration.
Klimscha S; Waldstein SM; Schlegl T; Bogunovic H; Sadeghipour A; Philip AM; Podkowinski D; Pablik E; Zhang L; Abramoff MD; Sonka M; Gerendas BS; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4039-4048. PubMed ID: 28813577
[TBL] [Abstract][Full Text] [Related]
11. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab.
Wolf A; Rüping J; Neubauer AS; Mayer W; Ulbig M; Haritoglou C; Holz FG; Eter N; Kampik A
Retina; 2013 Oct; 33(9):1843-9. PubMed ID: 23598795
[TBL] [Abstract][Full Text] [Related]
12. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.
Veritti D; Sarao V; Parravano M; Arias L; Varano M; Lanzetta P
Eur J Ophthalmol; 2017 Jan; 27(1):74-79. PubMed ID: 27791249
[TBL] [Abstract][Full Text] [Related]
13. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.
Ricci F; Parravano M; Regine F; Sciamanna M; Tedeschi M; Missiroli F; Varano M
Eye (Lond); 2016 Aug; 30(8):1077-83. PubMed ID: 27229701
[TBL] [Abstract][Full Text] [Related]
15. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
[TBL] [Abstract][Full Text] [Related]
16. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration.
Broadhead GK; Hong T; Zhu M; Li H; Schlub TE; Wijeyakumar W; Chang AA
Retina; 2015 May; 35(5):975-81. PubMed ID: 25627086
[TBL] [Abstract][Full Text] [Related]
17. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
18. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
de Massougnes S; Dirani A; Mantel I
Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
[TBL] [Abstract][Full Text] [Related]
19. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
